Dapagliflozin as add-on to metformin may reduce T2DM burden in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news
AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition
Dapagliflozin has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 29, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF
Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 27, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR
Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of ' fast decline ' of renal function in DECLARE-TIMI 58, the drug ' s main cardiovascular outcome trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 25, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients
Dapagliflozin cut the relative incidence of new-onset type 2 diabetes by one third in patients with heart failure in the multicenter trial.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 16, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
FDA OKs Farxiga for Heart Failure With Reduced Ejection Fraction
WEDNESDAY, May 6, 2020 -- The U.S. Food and Drug Administration has granted approval for Farxiga (dapagliflozin) oral tablets to treat adults with heart failure with reduced ejection fraction, the agency announced Tuesday.
Farxiga is the first... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2020 Category: General Medicine Source Type: news
FDA Approves Diabetes Drug for Type of Heart Failure
The FDA today approved a new use for the diabetes drug, dapagliflozin (Farxiga), to reduce the risk of a hospital stay or death in people who have a type of heart failure. (Source: WebMD Health)
Source: WebMD Health - May 6, 2020 Category: Consumer Health News Source Type: news
FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure
The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 -- AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2020 Category: Drugs & Pharmacology Source Type: news
New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19. (Source: WebMD Health)
Source: WebMD Health - May 1, 2020 Category: Consumer Health News Source Type: news
New Study of Diabetes Drug for COVID-19 Raises Eyebrows New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca ' s just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 30, 2020 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news
Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tablets
Glenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin and Saxagliptin anti-diabetes tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2020 Category: Pharmaceuticals Source Type: news
Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients.
The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2020 Category: Biotechnology Authors: Brian Kaberline Source Type: news
Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients.
The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2020 Category: Pharmaceuticals Authors: Brian Kaberline Source Type: news
